Insider · CIK 0001436861
Paolo Pucci
director
Files at WST (WEST PHARMACEUTICAL SERVICES INC), MRUS (Merus N.V.), REPL (Replimune Group, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | MRUS Merus N.V. | DDisposition to issuer Share Option (right to buy)derivative | -13,193 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Dec 12, 2025 | MRUS Merus N.V. | DDisposition to issuer Share Option (right to buy)derivative | -8,844 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Dec 12, 2025 | MRUS Merus N.V. | DDisposition to issuer Share Option (right to buy)derivative | -14,414 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Dec 12, 2025 | MRUS Merus N.V. | DDisposition to issuer Share Option (right to buy)derivative | -16,604 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Dec 12, 2025 | MRUS Merus N.V. | DDisposition to issuer Share Option (right to buy)derivative | -6,120 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Dec 12, 2025 | MRUS Merus N.V. | DDisposition to issuer Share Option (right to buy)derivative | -17,262 | $0.00 | $0 | 0 | Dec 12, 2025 |
| May 22, 2025 | MRUS Merus N.V. | AGrant or award Share Option (right to buy)derivative | +13,193 | $0.00 | $0 | 13,193 | May 27, 2025 |
| May 6, 2025 | WST WEST PHARMACEUTICAL SERVICES INC | AGrant or award Common Stock | +1,071 | $0.00 | $0 | 10,947 | May 8, 2025 |
| Apr 1, 2025 | REPL Replimune Group, Inc. | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.